Results of the recently conducted clinical studies have shown that sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce the risk of CHF in individuals having type 2 diabetes mellitus (T2DM) [4–9]. The gene discussed is SLC5A2; the disease is congestive heart failure.